Resources from the same session
1312O - From regulating off-label use to creating an environment for drug repurposing in oncology
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1313O - Assessment of investigational new drugs (INDs) approved in USA and Europe after early phase trials using the ESMO-magnitude of clinical benefit scale (ESMO-MCBS)
Presenter: Justin Moyers
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Invited Discussant 1312O and 1313O
Presenter: Panagiotis Kanavos
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Slides
Webcast
1314O - Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer: The MetAction precision medicine study
Presenter: Anne Ree
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1315O - Key learnings from building: A precision cancer medicine implementation initiative for Norway
Presenter: Kjetil Tasken
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1316O - Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network
Presenter: Jean-Yves Blay
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast